ERCP — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Endoscopic retrograde cholangiopancreatography (ERCP) is a combined endoscopic and fluoroscopic procedure used to examine and treat disorders of the bile ducts, gallbladder, and pancreatic duct. A flexible side-viewing duodenoscope — a long, thin camera with a working channel — is passed through the mouth, oesophagus, stomach, and into the second part of the duodenum, where the major duodenal papilla (ampulla of Vater) — the shared opening of the common bile duct and main pancreatic duct — is identified. A thin catheter is threaded into the desired duct and contrast dye injected under real-time X-ray fluoroscopy to image the ductal anatomy and identify pathology such as stones, strictures, leaks, tumours, or sclerosing disease. ERCP has evolved primarily into a therapeutic procedure since the advent of MRCP (magnetic resonance cholangiopancreatography) and endoscopic ultrasound (EUS) for diagnostic imaging — diagnostic ERCP without a therapeutic intent carries unnecessary risk and should rarely be performed. Approximately 500,000 ERCP procedures are performed annually in the United States alone. ERCP is technically demanding, with success rates highly dependent on operator experience; the procedure should be performed in centres completing at least 200 cases annually.

ERCP is indicated primarily for therapeutic interventions after non-invasive imaging has established the diagnosis. Common therapeutic indications include: common bile duct stones (choledocholithiasis) causing obstructive jaundice, cholangitis, or biliary pancreatitis — ERCP with sphincterotomy and stone extraction is the standard of care; malignant bile duct obstruction from pancreatic head cancer, cholangiocarcinoma, or metastatic disease requiring stent insertion for jaundice palliation; benign biliary strictures from post-surgical injury, primary sclerosing cholangitis (PSC), or chronic pancreatitis; bile duct leaks after cholecystectomy or liver surgery — sealed by stenting; and post-liver-transplant biliary complications (strictures, leaks, stones). Diagnostic indications include tissue sampling (brushings or biopsies) from biliary strictures to differentiate benign from malignant causes when other imaging is indeterminate. MRCP has replaced diagnostic ERCP for most imaging indications, carrying no procedural risk. Contraindications to ERCP include inability to safely pass the endoscope (severe oesophageal stricture, inaccessible papilla after Roux-en-Y gastric bypass requiring device-assisted enteroscopy), severe coagulopathy not correctable pre-procedure, and haemodynamic instability.

The patient is positioned prone or in the left lateral decubitus position. Conscious sedation — intravenous midazolam, fentanyl, and propofol — is standard; general anaesthesia may be used for complex cases or anxious patients. The duodenoscope is advanced to the second duodenum. The papilla is identified and a catheter (and guidewire) is introduced selectively into the common bile duct or pancreatic duct — selective cannulation of the desired duct is the critical technical step and requires precise angulation of the duodenoscope elevator. Contrast dye is injected and fluoroscopic images acquired. Therapeutic interventions are then performed through the working channel: sphincterotomy — an endoscopic incision through the sphincter of Oddi using a diathermy wire, widening the bile duct opening for stone passage or stent placement; stone extraction — dormia baskets and balloon catheters retrieve stones from the duct; balloon dilation of the papilla as an alternative to sphincterotomy in patients on anticoagulants; stent insertion — plastic or self-expanding metal stents are deployed across biliary or pancreatic strictures or bile leaks; brush cytology — cells are collected from strictures for cytological analysis. ERCP duration is 30–90 minutes. Fluoroscopy time is minimised; lead aprons are worn by all theatre staff. The complete ERCP procedure typically takes 30–90 minutes.

ERCP achieves successful bile duct access and cannulation in 90–95% of cases at expert centres, with stone clearance rates exceeding 90% for common bile duct stones in a single session — large stones (above 15 mm) may require mechanical lithotripsy or intraductal laser/electrohydraulic lithotripsy delivered through a cholangioscope. ERCP has replaced open biliary surgery for the vast majority of bile duct stone disease, transforming a procedure requiring general anaesthesia and abdominal surgery with 7–10 days hospitalisation into a day-case or overnight endoscopic procedure with 1–3 days recovery. For biliary obstruction from malignant strictures (cholangiocarcinoma, pancreatic cancer), ERCP stenting provides effective jaundice palliation in 85–90% of patients, significantly improving quality of life without surgery. Self-expanding metal stents (SEMS) remain patent for 6–12 months versus 3–4 months for plastic stents, and are preferred for malignant obstruction when surgery is not planned. Endoscopic sphincterotomy for common bile duct stones prevents recurrent cholangitis and biliary pancreatitis in the majority of patients, with long-term biliary event-free survival exceeding 85% at 5 years.

ERCP carries a complication rate of 5–10% in unselected populations — higher than most endoscopic procedures. Post-ERCP pancreatitis (PEP) is the most common complication, occurring in 3–5% of unselected cases and 10–15% in high-risk groups (sphincter of Oddi dysfunction, female sex, prior PEP, difficult cannulation). It is classified mild (24–48 hours of pain), moderate (4–7 days hospitalisation), or severe with necrosis. Prevention strategies with proven efficacy include rectal indomethacin 100 mg immediately post-procedure (reduces PEP by 50%), pancreatic duct stenting in high-risk cases, and aggressive periprocedural hydration with Ringer's lactate. Post-sphincterotomy bleeding occurs in 1–2% and is usually manageable endoscopically with injection therapy, clips, or coagulation. Perforation — duodenal or periampullary — occurs in 0.1–0.6% and may require surgical intervention. Cholangitis (ascending bile duct infection) following inadequate stone clearance or stent dysfunction occurs in 0.5–3% and requires antibiotics and urgent biliary decompression. Contrast allergy is uncommon with modern non-ionic contrast agents. Overall ERCP-related mortality is approximately 0.1–0.4% in experienced hands.

After ERCP, patients recover in a monitored area for 1–2 hours until the effects of sedation wear off and vital signs are stable. Blood tests including serum amylase and liver function tests (LFTs) are checked at 4–6 hours post-procedure. Most patients who undergo uncomplicated ERCP with stone clearance are discharged the same day or after one overnight stay. Abdominal discomfort after ERCP is common and usually mild; increasing pain in the first 12 hours, particularly radiating to the back, may indicate post-ERCP pancreatitis and requires escalation of analgesia and IV hydration, with a CT scan if severe. Diet can resume 2–4 hours after the procedure once swallowing reflexes are confirmed. Antibiotics are prescribed for any established cholangitis. Patients with plastic biliary stents require repeat ERCP for stent exchange every 3 months to prevent blocked stent cholangitis. Patients with metal stents for malignant obstruction require no routine exchange unless stent dysfunction occurs. Cholecystectomy (gallbladder removal) should be arranged within 2–6 weeks of ERCP for common bile duct stones with gallstones in situ to prevent recurrent gallstone-related complications.